Lipids & metabolic liver disease
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study
Main finding · Incident ASCVD during follow-upResult — go to the resultAdjusted hazard ratio 1.90 95% CI 1.49–2.42Authors' conclusion
Our findings suggest that the burden and risk of ASCVD are markedly lower in females than males with familial hypercholesterolaemia. The impact of sex needs to be considered to improve risk stratification and personalised management in patients with heterozygous familial hypercholesterolaemia.
Study context
- Population
- Adults aged ≥18 years with genetically confirmed familial hypercholesterolaemia in SAFEHEART, 25 tertiary care hospitals and one regional hospital in Spain; mean age 46.1 years
- Participants
- 3,506 adults
- Exposure
- Males vs females with heterozygous familial hypercholesterolaemia
- Malesn = 1,608
- Femalesn = 1,898reference
- Outcome
- Sex differences in risk and burden of atherosclerotic cardiovascular disease (ASCVD), over follow-up and over the life course
- Follow-up
- Median 10.3 years (IQR 6.4-13.0)
Methodological detailsnationwide, multicentre, long-term, Data obtained Jan 26, 2004, to Nov 30, 2022
- Nationwide
- Multicentre
- Long-term
- Data obtained Jan 26, 2004, to Nov 30, 2022
Main finding
Incident ASCVD during follow-up · median follow-up 10.3 years
Adjusted hazard ratio
1.90
95% CI 1.49–2.42
P < 0.0001
Events by group
As reported in the abstract
Observational data: associations, not effects.
Further findings
Mean on-treatment LDL-C · median follow-up
Absolute LDL-C reduction over time · similar in both sexes
P = 0.98
CVD at enrolment
P < 0.0001
| Outcome | Females | Males | Estimate | P value | |
|---|---|---|---|---|---|
| MACE-free survival from birthMACE-free survival lower in males · median, years | 90.1 (95% CI 86.5-not estimable) | 71.0 (95% CI 69.2–74.6) | HR for MACE 3.52 (95% CI 2.98–4.16) | P < 0.0001 | |
| Age at which 25% had a MACE | 74.9 years | 55.5 years | |||
| Cardiovascular death · during follow-up | aHR for cardiovascular death 1.74 (CI 1.11–2.73) | ||||
| 0.20.5125Ratio (log scale) |
Median age at first ASCVD event (mostly coronary artery disease)
P < 0.0001
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →